Depemokimab as adjunctive therapy for severe asthma with an eosinophilic phenotype in patients aged 12 years and older

Severe asthma is the most serious type of asthma where symptoms are hard to control, even with high doses of medicine. Severe asthma with an eosinophilic phenotype makes up approximately 50% of all severe asthmatic cases. It is characterised by tissue and sputum eosinophilia, which is when there are unusually high levels of eosinophils (a type of white blood cell) in the blood. Over the last 20 years, biological therapy for eosinophil diseases, including asthma, has improved. However, global treatment efficacy is still suboptimal. As novel therapies and biologic agents become available, there is an increased need for specific subtype-directed treatment strategies.